



CELLUMEN TO PRESENT AT SOCIETY OF TOXICOLOGY ANNUAL MEETING

Presentation to Address Critical Unmet Needs in Discovery Toxicology Applications

Pittsburgh, PA, March 9, 2009 – [Cellumen, Inc.](#), a discovery toxicology company, today announced that Donald P. Taylor, M.S., MBA, senior director of marketing and corporate development, will present at the [Society of Toxicology 48th Annual Meeting and ToxExpo™](#) on Wednesday, March 18, 2009 at 9:45 a.m. at the Baltimore Convention Center in Baltimore, MD.

Mr. Taylor will present discovery toxicology use-models for three current application areas: precedented targets, unprecedented targets and GLP/non-GLP animal study optimization. As part of this presentation, major unmet needs within each application will be discussed, and how Cellumen's [CellCiphr® CSB™ Toxicity Profiling Services](#) addresses those needs.

“The Society of Toxicology’s Annual Meeting is the largest gathering of toxicology experts,” says Donald Taylor. “Nominating pre-clinical candidates is one of the most important activities in drug development. With the right advanced discovery toxicology solutions in place, it has the ability to save the industry millions of dollars annually, and provide patients with safer, more effective drugs. Cellumen believes its CellCiphr technology is a mission-critical tool in drug development, and we look forward to sharing these three use-models to provide strong arguments for how and when to apply CellCiphr.”

The Society of Toxicology’s Annual Meeting is the largest toxicology meeting and exhibition in the world, attracting approximately 6,500 scientists from industry, academia, and government. The program includes a plenary and other special lectures, symposia, workshops, roundtable discussions, and platform and poster presentations. The meeting also offers continuing education courses ranging from basic to advanced levels. In addition, the Society presents annual awards to recognize outstanding achievements in toxicology.

About Cellumen

Cellumen is the leading collaborative partner and outsource service provider for the continuum of cell-based drug discovery and discovery toxicology solutions. Through its [CellCiphr® CSB™ Toxicity Profiling Services](#), Cellumen can predict the safest, most effective drugs in the drug discovery process, and as a result, reduce drug failure rates and cut development costs. Leading global organizations, including top pharmaceutical companies, the EPA, FDA, and NIH, partner with Cellumen. Cellumen is a partner company of [Safeguard Scientifics](#). Other investors include Novitas Capital, the Pittsburgh Life Sciences Greenhouse and Innovation Works. For more information about Cellumen, please visit www.cellumen.com.

Cellumen Media Contact

Theresa Murray

Gregory FCA

610-642-8253 x164

Theresa@GregoryFCA.com